Co-administered oral drugs

The term 'co-administered oral drugs' refers to the clinical practice of administering multiple therapeutic agents via the oral route simultaneously or within a short timeframe. This is not a specific biological target, such as a receptor or enzyme, but rather a pharmacological context that necessitates the evaluation of drug-drug interactions (DDIs) (FDA, 2020). Co-administration can significantly alter the pharmacokinetics of individual drugs through competition for absorption sites in the gastrointestinal tract, modulation of metabolic enzymes like Cytochrome P450 (CYP), or interference with transporter proteins like P-glycoprotein (Cascorbi, 2012). These interactions can lead to either sub-therapeutic plasma levels, resulting in treatment failure, or elevated concentrations that cause adverse drug reactions and toxicity (StatPearls, 2023). Understanding the implications of co-administered drugs is a critical component of clinical pharmacology and patient safety management, particularly in elderly populations where polypharmacy is common. In drug development, studies involving co-administered oral drugs are essential for establishing labeling requirements and dosing recommendations to mitigate risks (FDA, 2020).

Other names

Concomitant medicationsOral drug-drug interactionsPolypharmacyConcomitant oral drugs

Not applicable as this refers to a clinical scenario rather than a specific molecular target.